Top 10 Value Stocks To Invest In 2018

DryShips (DRYS) finally filed a 6-K after the close on July 25th that provided an update on its equity issuance for the period July 17th to July 25th. This was a break from prior disclosure patterns of providing updates on Fridays after the close or Mondays before the open as discussed in my article titled “Changing Its Disclosure Patterns?” The update on DRYS’ equity issuance was disappointing since the shares issued and the equity raised fell short of my expectations and, judging by the 20% losses in the stock into the late afternoon on July 26th, the market’s also. The following table summarizes the issuance for the period ending July 25th.

DryShips Equity Issuance Analysis Shares O/S July 7th (millions) 5.10 Funding Gap July 14th (millions) $5.56 Dates of Issuance July 17th – July 25th Shares Issued (millions) 14.08 Avg Issuance Price $1.88 July 25th Close $0.96 Shares O/S July 25th (millions) 19.18 Est of Value of Equity Issued $26.49

A close read of the 6-K reveals that most of the 14 million share issuance occurred July 21st through July 25th due to the pendency of the 1 for 7 reverse stock split announced on July 18th with an Effective Date of July 21st. The stock issued during this three day trading period equaled a bit more than 15% of the more than 91 million shares traded. Although this falls within the range of prior issuance percentages, it was a bit surprising that DRYS did not take advantage of the heavy trading volumes and price spikes and drive issuance closer to 20% of the shares traded. This resulted in lower equity proceeds than anticipated.

Top 10 Value Stocks To Invest In 2018: Arena Pharmaceuticals, Inc.(ARNA)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.09 percent. Meanwhile, top losers in the sector included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), down 6 percent, and Omeros Corporation (NASDAQ: OMER), down 5 percent.

  • [By Paul Ausick]

    Arena Pharmaceuticals Inc. (NASDAQ: ARNA) posted a new 52-week low of $1.20 on Tuesday, down about 19% compared with Monday’s closing price of $1.48. The stock’s 52-week high is $2.16. Volume was about 10% below the daily average of around 3.8 million shares. The company priced a secondary offering of 60 million shares at $1.15 per share, a path guaranteed to enrage existing investors.

  • [By Lisa Levin]

    Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) were down around 18 percent to $1.22. Arena Pharmaceuticals priced its 60 million share offering at $1.15 per share.

Top 10 Value Stocks To Invest In 2018: JA Solar Holdings, Co., Ltd.(JASO)

Advisors’ Opinion:

  • [By Monica Gerson]

    JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) is estimated to report its quarterly earnings at $0.68 per share on revenue of $683.29 million.

    Leju Holdings Ltd (ADR) (NYSE: LEJU) is projected to report its quarterly earnings at $0.14 per share on revenue of $194.20 million.

  • [By Travis Hoium]

    Earnings season is about over for the solar industry, and after JA Solar (NASDAQ:JASO) and Vivint Solar (NYSE:VSLR) reported this week, there were a few major takeaways from the end of 2016 and early 2017.

  • [By Elizabeth Balboa]

    First Solar, Inc (NASDAQ: FSLR) was trading down 3.7 percent Monday, while JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) was down 0.8 percent, SunPower Corporation (NASDAQ: SPWR) 4.4 percent, Canadian Solar Inc. (NASDAQ: CSIQ) 5.2 percent and JinkoSolar Holding Co., Ltd. (NYSE: JKS) 4.4 percent.

Top 10 Value Stocks To Invest In 2018: (PIONF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    International Lithium (ILC) is a small lithium explorer/project generator with four joint venture lithium projects, and one fully-owned lithium project:

    Mariana lithium brine in Argentina (20% ILC: 80% GFL). ILC can increase to 30% via a 10% back-in right. Jiangxi Ganfeng Lithium (GFL) is committed to US$10m in expenditures at Mariana. This is their flagship project. Avalonia lithium pegmatite in Ireland (45% ILC: 55% GFL). GFL has the option to acquire an additional 24% after spending US$10m, or producing a Feasibility Study [FS]. Mavis Lake and Raleigh lithium pegmatite in Ontario Canada (49% ILC: 51% Pioneer Resources Limited (OTC:PIONF)). 100% of the Forgan Lake pegmatite project in Canada.

    Note that Avalon, Mavis Lake, Raleigh, and Forgan Lake also have rare earths. Jiangxi Ganfeng Lithium (SHE:002460) has an 18.1% stake in ILC in addition to the above joint venture partnerships.

Top 10 Value Stocks To Invest In 2018: ThyssenKrupp AG (TYEKF)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    In addition, the company announced that it has agreed to acquire a steel plant in Brazil from ThyssenKrupp (NASDAQOTH:TYEKF) for $1.3 billion. While that plant has had its share of problems in the past, Ternium is getting it for a good value, and it has upside potential. The company paid slightly less than five times EBITDA (earnings before interest, taxes, depreciation, and amortization) for the facility. As the following chart shows, that’s below the value that steel-company stocks trade for these days:

Top 10 Value Stocks To Invest In 2018: Royal Bank Scotland plc (The)(RBS)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    European banks worse off than 2008? Lamensdorf is concerned about the exposure to bad loans (especially energy company debt) held by big banks such as Royal Bank of Scotland (RBS), Credit Suisse (CS) and Deutsche Bank (DB). He’s shorting all three.

  • [By Jonathan Morgan]

    Adidas AG slid 2.9 percent after lowering its profit forecast for 2013. Direct Line Insurance Group Plc lost 2.5 percent as Royal Bank of Scotland Group Plc (RBS) sold a 630 million-pound ($1 billion) stake in the U.K.s biggest car insurer.

Top 10 Value Stocks To Invest In 2018: Barclays PLC(BCS)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Barclays PLC (NYSE: BCS) was raised to Overweight from Equal Weight at Morgan Stanley. Its American depositary sharesclosed up 2.6% at $11.36 on Thursday and were indicated up 1.2% at $11.50 on Friday. The52-week range is $6.76 to $12.05.

  • [By WWW.THESTREET.COM]

    Banco Santander (SAN) : “I prefer Barclays (BCS) , but let’s wait and see what the other banks have to say”

    ProLogis (PLD) : “I am not a fan of that group right now, but that one is best of breed.”

Top 10 Value Stocks To Invest In 2018: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Several big-name biotech companies step into the earnings confessional starting in the middle of the week, with Amgen, Inc. (NASDAQ: AMGN), Anthem Inc (NYSE: ANTM), and Celgene Corporation (NASDAQ: CELG) among the companies in play. That could bring opportunity with the  Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD).

  • [By Stavros Georgiadis]

    Gilead Sciences (NSDQ:GILD) has underperformed the market with its stock price down almost 25% compared to a 10.33% gain in Nasdaq Composite (INDX:COMPX) and 14.60% gain of Dow Jones Industrial Average (INDX:INDU). Gilead and Amgen (NSDQ:AMGN)have had a very tough year, so it is interesting to know if now is the time to invest in GILD stock, not from a bottom fishing point of investing, which is often too risky, but on some solid financial and fundamentals arguments.

  • [By Ben Levisohn]

    What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.

  • [By Tom Gentile]

    After the Senate scored the votes on Tuesday to review a plan for repealing or repealing and replacing what’s come to be known as Obamacare, we saw a mixed-bag reaction from healthcare stocks. Even some of the bulletproof ones, like Amgen Inc. (Nasdaq: AMGN), closed lower from their opening highs.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is expected to report its most recent quarterly results on Wednesday. The consensus estimates call for $3.00 in EPS and $5.61 billion in revenue. Shares closed trading at $160.41 on Friday, in a 52-week range of $133.64 to $184.21. The consensus price target is $185.13.

Top 10 Value Stocks To Invest In 2018: Jacobs Engineering Group Inc.(JEC)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was Jacobs Engineering Group Inc. (NYSE: JEC) which rose about 9% to $64.92. The stocks 52-week range is $49.31 to $65.29. Volume was1.8 million compared to its average volume of less than 1 million.

  • [By Ben Levisohn]

    Lee offers 22 stocks that could benefit from the correlation trade: Western Digital (WDC), Xerox (XRX), First Solar, Ford Motor, Best Buy (BBY), PulteGroup (PHM), AutoNation (AN), Textron (TXT), Jacobs Engineering Group (JEC), Mosaic, BB&T (BBT), Fifth Third Bancorp (FITB),Loews (L), Regions Financial (RF), KeyCorp (KEY), Comerica (CMA), Leucadia National (LUK), Zions Bancorp (ZION), Valero Energy (VLO), Marathon Oil, Cardinal Health (CAH), and Pepco Holdings (POM).

Top 10 Value Stocks To Invest In 2018: Cytokinetics, Incorporated(CYTK)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares surged 30.2 percent to $5.01 after dropping 40.86 percent on Tuesday. Marathon Patent Group filed for sale of 1.85 million shares of common stock by selling stockholders.
    Capricor Therapeutics Inc (NASDAQ: CAPR) shares jumped 17.2 percent to $2.25 after the company reported the FDA clearance of Investigational New Drug application for CAP-1002.
    Rite Aid Corporation (NYSE: RAD) gained 13.2 percent to $2.15 following 16.5 percent rally on Tuesday.
    Photronics, Inc. (NASDAQ: PLAB) shares climbed 11.8 percent to $10.45 after the company reported stronger-than-expected earnings for its fourth quarter.
    China Distance Education Hldgs Ltd (ADR) (NYSE: DL) shares surged 11.3 percent to $8.67. China Distance Education reported Q4 profit of $5.9 million on revenue of $41.7 million.
    Cytokinetics, Inc. (NASDAQ: CYTK) shares gained 11 percent to $8.05 after falling 7.05 percent on Tuesday.
    Ooma Inc (NYSE: OOMA) shares surged 8.5 percent to $10.85 as the company posted strong Q3 results.
    Nuance Communications Inc. (NASDAQ: NUAN) climbed 8 percent to $17.12 after the company reported stronger-than-expected results for its fourth quarter on Tuesday.
    American Superconductor Corporation (NASDAQ: AMSC) surged 7.8 percent to $3.59 after the company reported $8 million in D-VAR system orders.
    Thermon Group Holdings Inc (NYSE: THR) rose 6.3 percent to $24.17. William Blair upgraded Thermon Group from Market Perform to Outperform.
    Domino's Pizza, Inc. (NYSE: DPZ) surged 6.1 percent to $182.88. Nomura upgraded Domino's from Neutral to Buy.
    Xencor Inc (NASDAQ: XNCR) rose 5.9 percent to $21.17. Cantor Fitzgerald initiated coverage on Xencor with an Overweight rating.
    Idera Pharmaceuticals Inc (NASDAQ: IDRA) gained 5.1 percent to $2.28 after the company disclosed that it has been granted FDA Fast Track designation for IMO-2125.
    Regal Entertainment Group (NYSE: RGC) gained 5.1 percent to
  • [By Paul Ausick]

    Cytokinetics Inc. (NASDAQ: CYTK) dropped about 37% Tuesday to post a new 52-week low of $7.00 after closing at $11.10 on Monday. The 52-week high is $17.20. Volume was around 7 million, about 14 times the daily average of less than 500,000. The company’s ALS drug failed ti meet its endpoint in a phase 3 study.

  • [By Lisa Levin]

    Cytokinetics, Inc. (NASDAQ: CYTK) shares dropped 27 percent to $8.12 on the back of negative trial results for its amyotrophic lateral sclerosis, or ALS, treatment candidate tirasemtiv in a late-stage study. The results of the international Phase 3 study showed tiraemtive did not meet the primary endpoint of change from baseline in slow vital capacity, or SVS, evaluated at 24 weeks, as well the secondary endpoints evaluated at 48 weeks.

  • [By Chris Lange]

    Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesdays session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS). Specifically, the firms Phase 3 clinical trial of tirasemtiv did not meet the primary endpoint or any of the secondary endpoints.

Top 10 Value Stocks To Invest In 2018: Tenneco Inc.(TEN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of auto-part makers like Delphi Automotive (DLPH), BorgWarner (BWA), and Tenneco (TEN) are getting killed today, ostensibly due to an article in Automotive News. Wells Fargo’s Richard Kwas and team think Tesla Motors (TSLA) and its Model 3 deserve at least some of the blame:

Leave a Reply

Your email address will not be published. Required fields are marked *